Gene Therapy: Moving Toward Commercialization

NEEDHAM, MA--(Marketwired - May 11, 2016) - Insight Pharma Reports, a division of Healthtech Publishing, releases "Gene Therapy: Moving Toward Commercialization" an in-depth life science market report outlining the progress of the gene therapy field, a field that is being a "hot" area with intense competition to develop and market breakthrough gene therapies.

The top questions that the Gene Therapy: Moving Toward Commercialization report asked in this detailed report included:

• Can gene therapy can attain commercial success by the early-to-mid 2020s
• Which types of gene therapy programs have the greatest likelihood of success
• What hurdles might stand in the way of clinical and commercial success of leading gene therapy programs

Exclusive to this report is:

• An interview with Sam Wadsworth, Ph.D., the Chief Scientific Officer of Dimension Therapeutics and former Head of Gene Therapy R&D at Genzyme, learn more from his 20 years of working in gene therapy
• Survey data from 88 researchers involved in gene therapy sharing feedback and insight
• Companies profiled: uniQure, Voyager Therapeutics, Oxford BioMedica, GeneQuine Therapeutics, Celladon Corporation, and bluebird

Topics covered within the Gene Therapy: Moving Toward Commercialization report include:

• Development of improved vectors (integrating and non-integrating vectors)
• Gene therapy for ophthalmological diseases
• Gene therapy for other rare diseases
• Clinical-stage gene therapies for selected rare diseases other than hemophilias
• Gene therapy for more common diseases
• Companies whose central technology platform involves ex vivo gene therapy
• CAR T-cell immunotherapy as an area of ex vivo gene therapy
• Gene editing technology
• Outlook for gene therapy
• Market outlook for eight gene therapy products

For more information on the Gene Therapy: Moving Toward Commercialization report, visit: www.insightpharmareports.com/Gene-Therapy-Report

About Insight Pharma Reports (www.insightpharmareports.com)

Insight Pharma Reports, a division of Healthtech Publishing, is the premier life sciences information provider offering unparalleled coverage of key issues in drug discovery and development. The reports are used by leading pharmaceutical, biotech, diagnostic, and other life science companies to keep abreast of the latest developments in pharmaceutical R&D and their potential applications and business impacts. The reports are written by experts in consulting and industry, and are supported by hundreds of hours of primary and secondary research. Insight Pharma Reports provide comprehensive coverage of salient issues in a concise, well-organized format.

About Healthtech Publishing (www.healthtechpublishing.com)

Healthtech Publishing, a division of Cambridge Healthtech Institute, provides the life science communities with business critical intelligence through research reports and digital news, helping decision makers to gain competitive advantage and make strategic decisions. Our portfolio consists of Insight Pharma Reports' vast research reports collection and three niche digital subscription products: Bio-IT World, Clinical Informatics News and Diagnostics World.